ERBB2 and cancer: Despite the presence of the HER2 molecule, monoclonal antibody therapy is unsuccessful in almost 50% of patients, which, given the high value of the Ki-67 index noted in this cancer, and which indicates increased proliferation, implies a poor prognosis [154,155,156].